This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Latanoprost.
|
Errors
editThis pages contains errors. Latanoprost is a prostaglandin 2 alpha agonist. Second, the structure is misleading: the hydroxyl groups are shown without Hydrogen.
I removed the comment about latanoprost being a growth factor analog.
Xalatan Patent Expiry
editThe article states the Xalatan patent expires in 2011. I see multiple similar references on the web, but after encountering an apparent real life generic Xalatan, I went looking and found a reference that says 9/2009 [1]. Perhaps this is due to what's said in this patent 4,599,353 extension from 1998: [2].
On the other hand, there are references to a newer related patent: 5,296,504. I think this one expires in 2011 (see [3]). And there's yet another: 5,422,368, but it looks like it might have been ruled unenforceable in 2004 [4].
In summary, I'm not sure about the whole thing. :) —Preceding unsigned comment added by 94.230.83.179 (talk) 14:09, 14 September 2009 (UTC)
Inventor
editLazlo Bito et al was the ones first having the idea of using prostaglandins to treat glaucoma. The drug Latanoprost was developed by Johan Stjernschantz and Bahram Resul at Pharmacia. — Preceding unsigned comment added by 130.238.122.15 (talk) 08:20, 16 August 2011 (UTC)
Yes, and there is a Wikipedia article on [[5]]. Seems like this article should mention him, and link to that article. That article, while it mentions Glaucoma, does not mention latanoprost (but does mention Xalatan) and has no link to this article - which it seems it should. The NYT did an obituary on 27 Nov 2021. Captain Puget (talk) 20:34, 30 November 2021 (UTC)
Confused about "Storage" recommendations
editThe "Storage" section currently implies that latanoprost's breakdown rates at 50 °C (122 °F) and 70 °C (158 °F) lead to the requirement "to store Latanoprost ideally in temperature below room temperature and free from sunlight". I've never heard such high temperatures being considered "room temperature". At first I thought someone had erred on or vandalized the units, but the LWW.com abstract includes these statements nearly verbatim. However, the abstract also states that latanoprost is stable at 25 °C (77 °F), which is a little higher than the conventional meaning of "room temperature", around 21 °C or 70 °F. This would seem to suggest that there's no need to store it in a cooler place (although the sunshine avoidance would still apply).
Does anyone have access to the original article to see if there's an explanation for why the temperature tests and conclusion seem to disagree? ~ Jeff Q (talk) 01:09, 15 November 2014 (UTC)
FDA approved storage says: Protect from light. Store unopened bottles at 2 to 6 °C (36 to 46 °F). During shipment, may be exposed to temperatures up to 40 °C (104 °F) for up to 8 days. Upon opening, bottle may be stored at room temperature up to 25 °C (77 °F) for 6 weeks. This info is extracted from the Sandoz/Alcon Laboratories package insert dated July 2012. 100.14.92.177 (talk) 16:41, 5 October 2015 (UTC)
Replaced primary with secondary source
editNot sure why User:RNbty10 restored the primary source and removed the secondary source?
Doc James (talk · contribs · email) 22:54, 17 October 2019 (UTC)